Added to YB: 2026-10-05
Pitch date: 2026-10-01
ERF.PA [neutral]
Eurofins Scientific SE
+6.97%
current return
Author Info
Lux Opes Research covers European companies. Lots of them. Sign up for the newsletter.
Company Info
Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide.
Market Cap
EUR 13.0B
Pitch Price
EUR 74.00
Price Target
N/A
Dividend
0.96%
EV/EBITDA
10.02
P/E
29.32
EV/Sales
2.29
Sector
Life Sciences Tools and Services
Category
turnaround
Eurofins (ERF France): Biopharma recovery remains delayed
ERF.PA (update): Eurofins’ Life business continues to improve, but Biopharma remains subdued as biotech financing constraints and contract delays defer recovery; management expects conditions to improve gradually from end-2026 as signed contracts begin contributing and comparisons ease. Management still targets mid-single-digit 2026 organic growth, roughly €250m of acquired revenue and margin above 2025’s 22.5%, though the timing of Biopharma’s needed contribution remains uncertain ahead of the 21 October Q3 update.
Read full article (2 min)